BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
The company focused on developing a novel, reversible, all-endoscopic surgical set of tools, which would serve as a safe and simple alternative to surgical treatment for obesity. Their trans-oral solution would avoid complications and safety issues related to conventional incision-based surgery for obesity. The company's assets were sold in 2013.
BaroSense
Menlo Park, CA
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.